# Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

> **NCT04623242** · PHASE2,PHASE3 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 194 (actual)

## Conditions studied

- Alzheimers Disease
- Dementia
- Alzheimers Disease, Familial

## Interventions

- **DRUG:** Gantenerumab
- **DRUG:** Solanezumab
- **DRUG:** Matching Placebo (Gantenerumab)
- **DRUG:** Matching Placebo (Solanezumab)

## Key facts

- **NCT ID:** NCT04623242
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2019-11-22
- **Final completion:** 2020-03-06
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2022-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623242, "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04623242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*